References: 1. Data on file, Tarsus Pharmaceuticals Inc. June 2022. 2. Trattler W, Karpecki P, Rapoport Y, et al. The prevalence
of Demodex blepharitis in US eye care clinic patients as determined by collarettes: a pathognomonic sign. Clin Ophthalmol.
2022;16:1153-1164. 3. Saydah SH, Gerzoff, RB, Saaddine JB, Zhang X, Cotch MF. Eye care among US adults at high risk for vision
loss in the United States in 2022 and 2017. JAMA Ophthalmol. 2020;138(5):479-489.
© 2022 Tarsus Pharmaceuticals, Inc. TARPRE-DB-0013 9/22
We're willing to bet most eye care
professionals don't realize just how
prevalent Demodex blepharitis is.
1
In fact, ~25 million eye care patients are affected by Demodex blepharitis (DB).
2, 3
